Ulrich Moebius

Ulrich Moebius is an expert in developing drug candidates from research through nonclinical development into early phases of clinical development. He graduated with a Ph.D. in immunology and completed 10 years of academic research at the German Cancer Research Center in Heidelberg, Germany and the Dana Farber Cancer Institute in Boston, MA, USA, with a focus on immune cell function and immune oncology.

Before joining SOTIO in 2016, Ulrich worked for 19 years at various German Biotech companies such as MediGene, Morphosys and Pieris with responsibilities for nonclinical development, project management and entire R&D activities. He was also responsible for nonclinical packages of different drug candidates, including small molecules, cell vaccines and biologics, enabling the initiation of clinical development in mainly oncology but also autoimmune indications. Early clinical development activity in managing Phase 1/II studies complement his experience.